Importance of Disrupted Intestinal Barrier in Inflammatory Bowel Diseases

被引:573
作者
Salim, Sa'ad Y. [1 ]
Soderholm, Johan D. [1 ]
机构
[1] Linkoping Univ, Fac Hlth Sci, Div Surg & Clin Oncol, Dept Clin & Expt Med, Linkoping, Sweden
基金
瑞典研究理事会;
关键词
intestinal mucosal barrier; intestinal permeability; CD; UC; IBD; EPITHELIAL TIGHT JUNCTION; NECROSIS-FACTOR-ALPHA; FOLLICLE-ASSOCIATED EPITHELIUM; GLUCAGON-LIKE PEPTIDE-2; ACTIVE CROHNS-DISEASE; HORSERADISH-PEROXIDASE TRANSPORT; NONPATHOGENIC ESCHERICHIA-COLI; GENOME-WIDE ASSOCIATION; CHAIN KINASE EXPRESSION; CYTOKINE MESSENGER-RNA;
D O I
10.1002/ibd.21403
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
The current paradigm of inflammatory bowel diseases (IBD), both Crohn's disease (CD) and ulcerative colitis (UC), involves the interaction between environmental factors in the intestinal lumen and inappropriate host immune responses in genetically predisposed individuals. The intestinal mucosal barrier has evolved to maintain a delicate balance between absorbing essential nutrients while preventing the entry and responding to harmful contents. In IBD, disruptions of essential elements of the intestinal barrier lead to permeability defects. These barrier defects exacerbate the underlying immune system, subsequently resulting in tissue damage. The epithelial phenotype in active IBD is very similar in CD and UC. It is characterized by increased secretion of chloride and water, leading to diarrhea, increased permeability via both the transcellular and paracellular routes, and increased apoptosis of epithelial cells. The main cytokine that seems to drive these changes is tumor necrosis factor alpha in CD, whereas interleukin (IL)-13 may be more important in UC. Therapeutic restoration of the mucosal barrier would provide protection and prevent antigenic overload due to intestinal "leakiness.'' Here we give an overview of the key players of the intestinal mucosal barrier and review the current literature from studies in humans and human systems on mechanisms underlying mucosal barrier dysfunction in IBD.
引用
收藏
页码:362 / 381
页数:20
相关论文
共 292 条
[1]
Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[2]
Advances in methods to evaluate gastrointestinal transport function [J].
Albin, DM ;
Tappenden, KA .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2001, 4 (05) :351-354
[3]
Inflammatory bowel disease: new insights into pathogenesis and treatment [J].
Ardizzone, S ;
Porro, GB .
JOURNAL OF INTERNAL MEDICINE, 2002, 252 (06) :475-496
[4]
Arnott IDR, 2000, SCAND J GASTROENTERO, V35, P1163
[5]
Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse [J].
Arrieta, M. C. ;
Madsen, K. ;
Doyle, J. ;
Meddings, J. .
GUT, 2009, 58 (01) :41-48
[6]
51CrEDTA colonic permeability and therapy response in patients with ulcerative colitis [J].
Arslan, G ;
Atasever, T ;
Cindoruk, M ;
Yildirim, IS .
NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (09) :997-1001
[7]
Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut [J].
Artis, David .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (06) :411-420
[8]
The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo [J].
Atuma, C ;
Strugala, V ;
Allen, A ;
Holm, L .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2001, 280 (05) :G922-G929
[9]
The gut microbiota as an environmental factor that regulates fat storage [J].
Bäckhed, F ;
Ding, H ;
Wang, T ;
Hooper, LV ;
Koh, GY ;
Nagy, A ;
Semenkovich, CF ;
Gordon, JI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (44) :15718-15723
[10]
BAKER J, 1993, J CELL SCI, V104, P415